REPL Logo

Replimune Group, Inc. (REPL) 

NASDAQ$11.655
Market Cap
$897.61M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
805 of 924
Rank in Industry
455 of 527

REPL Insider Trading Activity

REPL Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$000
Sells
$1,103,14312100

Related Transactions

Schwendenman AndrewChief Accounting Officer0$01$14,868$-14,868
Sarchi ChristopherChief Commercial Officer0$02$70,482$-70,482
Coffin Robertdirector0$01$74,172$-74,172
Hill Emily LuisaChief Financial Officer0$01$90,989$-90,989
Love ColinChief Operating Officer0$01$113,969$-113,969
Xynos KonstantinosChief Medical Officer0$03$238,414$-238,414
Astley-Sparke PhilipExecutive Chairman0$01$245,394$-245,394
Patel SushilChief Executive Officer0$02$254,855$-254,855

About Replimune Group, Inc.

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing â€¦

Insider Activity of Replimune Group, Inc.

Over the last 12 months, insiders at Replimune Group, Inc. have bought $0 and sold $1.1M worth of Replimune Group, Inc. stock.

On average, over the past 5 years, insiders at Replimune Group, Inc. have bought $0 and sold $15.69M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,100,000 shares for transaction amount of $14.97M was made by Rhodes Jason P (director) on 2019‑11‑18.

List of Insider Buy and Sell Transactions, Replimune Group, Inc.

2024-12-16SalePatel SushilChief Executive Officer
10,000
0.0132%
$12.42$124,200+0.64%
2024-11-18SaleXynos KonstantinosChief Medical Officer
7,246
0.0106%
$10.78$78,112+17.36%
2024-11-18SaleSarchi ChristopherChief Commercial Officer
5,207
0.0076%
$10.78$56,131+17.36%
2024-08-16SaleHill Emily LuisaChief Financial Officer
8,938
0.0137%
$10.18$90,989+18.30%
2024-06-07SaleXynos KonstantinosChief Medical Officer
15,881
0.0245%
$7.50$119,108+43.42%
2024-05-16SaleCoffin Robertdirector
11,464
0.0189%
$6.47$74,172+65.63%
2024-05-16SaleAstley-Sparke PhilipExecutive Chairman
37,928
0.0626%
$6.47$245,394+65.63%
2024-05-16SaleLove ColinChief Operating Officer
17,615
0.0291%
$6.47$113,969+65.63%
2024-05-16SalePatel SushilChief Executive Officer
20,194
0.0333%
$6.47$130,655+65.63%
2024-05-16SaleXynos KonstantinosChief Medical Officer
6,367
0.0105%
$6.47$41,194+65.63%
2024-05-16SaleSarchi ChristopherChief Commercial Officer
2,218
0.0037%
$6.47$14,350+65.63%
2024-05-16SaleSchwendenman AndrewChief Accounting Officer
2,298
0.0038%
$6.47$14,868+65.63%
2023-11-16SaleXynos KonstantinosChief Medical Officer
7,313
0.0131%
$10.92$79,858-15.60%
2023-11-16SaleSarchi ChristopherChief Commercial Officer
5,255
0.0094%
$10.92$57,385-15.60%
2023-09-12SaleEsposito PamelaChief Business Officer
300
0.0005%
$20.00$6,000-54.46%
2023-09-11SaleEsposito PamelaChief Business Officer
5,358
0.0092%
$20.01$107,214-55.86%
2023-08-22SaleEsposito PamelaChief Business Officer
18,600
0.0315%
$20.01$372,186-56.41%
2023-08-11SaleEsposito PamelaChief Business Officer
1,400
0.0024%
$20.00$28,000-56.32%
2023-07-10SaleEsposito PamelaChief Business Officer
20,000
0.035%
$21.58$431,541-58.78%
2023-06-13SalePatel SushilChief Strategy Officer
5,698
0.0098%
$24.05$137,008-62.63%
Total: 131
*Gray background shows transactions not older than one year

Insider Historical Profitability

12.92%
Omega Fund IV, L.P.
4763380
6.185%
$55.52M220+27.98%
Slootweg Hugo Alexander
4721449
6.1306%
$55.03M10<0.0001%
Forbion Capital Fund III Cooperatief U.A.10 percent owner
4721449
6.1306%
$55.03M10<0.0001%
Bain Capital Life Sciences Investors, LLC10 percent owner
2838968
3.6863%
$33.09M10<0.0001%
Rhodes Jason Pdirector
946000
1.2283%
$11.03M111+63.12%

Historical Insider Profitability vs. Competitors

$7,929,017
58
21.56%
$787.18M
$571,084,134
44
4.33%
$988.55M
$97,176
41
42.84%
$802.16M
$28,907,358
35
41.41%
$899.09M
$530,111,731
35
8.67%
$1.09B

REPL Institutional Investors: Active Positions

Increased Positions101+78.91%16M+22.93%
Decreased Positions50-39.06%6M-8.91%
New Positions35New6MNew
Sold Out Positions19Sold Out1MSold Out
Total Postitions179+39.84%80M+14.02%

REPL Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Baker Bros. Advisors Lp$140,055.0014.35%11.05M00%2024-12-31
Price T Rowe Associates Inc /Md/$139,009.0014.24%10.96M+1M+10.97%2024-12-31
Blackrock, Inc.$70,582.007.23%5.57M+94,833+1.73%2024-12-31
Redmile Group, Llc$62,202.006.37%4.91M+124,344+2.6%2024-12-31
Fcpm Iii Services B.V.$50,348.005.16%3.97M-895,781-18.41%2024-12-31
Vanguard Group Inc$45,595.004.67%3.6M+129,601+3.74%2024-12-31
Sofinnova Investments, Inc.$39,936.004.09%3.15M+3M+6,442.69%2024-12-31
Tang Capital Management Llc$34,236.003.51%2.7M+2M+125%2024-12-31
State Street Corp$27,947.002.86%2.2M-135,991-5.81%2024-12-31
Rtw Investments, Lp$26,184.002.68%2.07M+931,223+82.13%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.